PepTrackevidence-graded reference
Retatrutide
fig.1 — stylized molecular motif
Metabolic

Retatrutide

LY-3437943 · triple-G · Godzilla

Hottest gray-market 'research peptide' name; huge Reddit/TikTok. Phase-3 TRIUMPH-1 topline (21 May 2026): 28.3% at 12 mg/80 wk (efficacy estimand; ~25% treatment-regimen).

Evidence
Bhuman trials
Status
Investigationalas of 2026-06
Approval
Not approved
Category
Metabolic
Route
Subcutaneous
Demand rank
#3 most-searched
01Dosing & Protocol
Typical · reference only
Trial targets 4/9/12 mg weekly; community typically settles 4-8 mg weekly, starts far lower (0.25-0.5 mg)
Titration
346912 mg↑ dose · → time (≈4-week steps)
Reconstitution — illustrative, not a recommendation
10 mg vial + 1 mL BAC = 10 mg/mL; 1 mg = 10 U; 12 mg = 120 U (exceeds 100-U syringe). Valid only if vial truly contains labeled mg.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Not approved; est. filing Q4'26-Q1'27. Gray-market 'research' vials are unapproved-new-drug territory.
Pre-clinical
Phase 1
Phase 2
Phase 3
Approved
Status
Investigational
503A bulks
Not on the bulks list
Category 2
n/a (investigational; cannot be compounded)
PCAC review
none scheduled
WADA
Not listed
03Evidence — the honest read
What the evidence actually shows

Late Phase 3 topline (company press release; not peer-reviewed). Dose-dependent dysesthesia (~21% high dose); cardiac arrhythmia signal in Phase 2.

04Safety
Contraindications
  • MTC/MEN-2 (class-extrapolated)
  • Pregnancyhard stop
  • Pancreatitis history
Key interactions
  • Insulin/sulfonylureas -> hypoglycemia (it LOWERS glucose net; glucagon arm offset by GLP-1/GIP)
  • Anesthesia -> aspiration
Serious signals
  • Dysesthesia at high dose
  • Cardiac arrhythmia imbalance (Phase 2)
  • Elevated HR
Monitoring
Glucose/HbA1c; HR; hold before surgery.
05Related in Metabolic
Semaglutide
FDA-approved RCTs
grade A →
Tirzepatide
FDA-approved RCTs
grade A →
Cagrilintide / CagriSema
human trials
grade B →
MOTS-c
animal-only
grade D →
06Sources
1ajmc.com TRIUMPH-1
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: high (trial data) / low (gray-market dosing)
← All peptides
Metabolic

Retatrutide

LY-3437943 · triple-G · Godzilla

Hottest gray-market 'research peptide' name; huge Reddit/TikTok. Phase-3 TRIUMPH-1 topline (21 May 2026): 28.3% at 12 mg/80 wk (efficacy estimand; ~25% treatment-regimen).

Evidence
B
human trials
Status
Investigational
as of 2026-06
FDA approval
Not approved
off-label / gray
Route
Subcutaneous
Community / anecdotal
Demand
#3
most-searched
WADA
Not listed
sport-legal
01

Dosing & protocol

Community / anecdotal. Community / anecdotal — no regulatory basis. Not medical advice.
Typical — reference only

Trial targets 4/9/12 mg weekly; community typically settles 4-8 mg weekly, starts far lower (0.25-0.5 mg)

Worked reconstitution example

10 mg vial + 1 mL BAC = 10 mg/mL; 1 mg = 10 U; 12 mg = 120 U (exceeds 100-U syringe). Valid only if vial truly contains labeled mg.

Titration
0369123wk 14wk 56wk 99wk 1312 mgwk 17dose (mg) ↑time → (≈4-week steps)
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial (use the calculator →).
02

Regulatory status

Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Not approved; est. filing Q4'26-Q1'27. Gray-market 'research' vials are unapproved-new-drug territory.
Pre-clinical
Phase 1
Phase 2
Phase 3
Approved
StatusInvestigational
503A bulksNot on the bulks list
Category 2 (2026)n/a (investigational; cannot be compounded)
PCAC reviewnone scheduled
WADANot listed
03

Evidence — the honest read

Bhuman trials

Late Phase 3 topline (company press release; not peer-reviewed). Dose-dependent dysesthesia (~21% high dose); cardiac arrhythmia signal in Phase 2.

04

Safety

Contraindications
  • MTC/MEN-2 (class-extrapolated)
  • Pregnancyhard stop
  • Pancreatitis history
Key interactions
  • Insulin/sulfonylureas -> hypoglycemia (it LOWERS glucose net; glucagon arm offset by GLP-1/GIP)
  • Anesthesia -> aspiration
Serious signals
  • Dysesthesia at high dose
  • Cardiac arrhythmia imbalance (Phase 2)
  • Elevated HR
Monitoring

Glucose/HbA1c; HR; hold before surgery.

06

Sources

01ajmc.com TRIUMPH-1
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: high (trial data) / low (gray-market dosing)